VRITIMES
SG
Raise It With Press Release
TechnologyCommerce / LifestyleFood / BeverageEducationReal Estate / Architecture
Get Guaranteed Publications in minimum 35 Media Outlets for Just S$50 S$25
Try it >>
press release

/ Austrianova Expands Facilities in Singapore and Thailand

Austrianova Expands Facilities in Singapore and Thailand

Austrianova
Austrianova (SGAustria), a leading provider of cell encapsulation and cell biological products and services, today announced details about the expansion of its facilities in Thailand and Singapore as a result of recent financing.
preview

SINGAPORE, 3 April, 2023

Austrianova (SGAustria), a leading provider of cell encapsulation as well as biological products and services, today announced details concerning the expansion of its facilities and capacity in Thailand and Singapore.

Over the last few months, the company has increased its capacity at its facility at Thailand Science Park (TSP), in Pathumthani, Thailand. This metro Bangkok location is where Austrianova Thailand has its state-of-the-art GMP and ISO9001:2015 qualified production suites and R&D labs. The TSP facility focuses on Austrianova's Cell-in-a-Box® cell encapsulation technology platform for protection of human and animal cells from immune rejection and clearance when implanted in the body, as well as for long-term storage in the frozen state. Besides working together with partners and clients who use the Cell-in-a-Box® technology, the facility also produces cell banks and other cell therapy related products.

Austrianova Singapore focuses on the company's Bac-in-a-Box® encapsulation technology for the protection of bacteria and yeast cells. This technology allows bacteria and yeast to be (i) stored at room temperature without appreciable loss in viability and (ii) protected from the harmful, sterilizing effects of stomach acid. Bac-in-a-Box® encapsulation is used in diverse applications such as animal feed optimisation, cosmeceuticals for skin health, and human and animal probiotics, as well as in the modification of the microbiome by selective and efficient delivery of bacteria to treat dysbiosis of the gastric tract. Austrianova Singapore is also gearing up to expand its facility in Singapore for pilot scale production of Bac-in-a-Box® based bacterial and yeast products.

Walter H. Gunzburg, Chairman of Austrianova, said “The increase in capacity at our two facilities is driven by an increasing demand for Austrianova’s signature Cell-in-a-Box® and Bac-in-a-Box® platforms.”

Austrianova CEO, Brian Salmons, added “Austrianova was awarded ISO 9001:2015 certification a year ago and we recently successfully completed our ISO 9001:2015 Quality Management System audit. The scope of this certification is being expanded going forward to reflect the expansion of our activities.”

Forward-Looking Statements

This release includes forward-looking statements regarding Austrianova/SGAustria (the Company) and its respective businesses. Such statements are based on the current expectations of the management of each entity. The forward-looking events and circumstances discussed in this release, including completion of the public offering, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks affecting the Company, economic factors and the equity markets generally. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Austrianova undertakes no obligation to publicly up-date or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. This is not an offer or solicitation to buy or sell any securities.

SOURCE Austrianova

Financial Information Contact: pierre.faddoul@square-associates.com

Company and Technology Contact: information@austrianova.com

For more information: http://www.austrianova.com

Cell-in-a-Box® Production at Austrianova Thailand's GMP Facility
Cell-in-a-Box® Production at Austrianova Thailand's GMP Facility
About Austrianova
About Austrianova Austrianova (the SGAustria Group), is a biotech company with a global footprint and operations in Singapore and Thailand. Austrianova utilizes a novel and proprietary technology for the encapsulation of living mammalian (Cell-in-a-Box®) and bacterial (Bac-in-a-Box®) cells. Cell-in-a-Box® protects the encapsulated cells from rejection by the immune system, allows cells to be easily transported, stored and implanted at specific sites in patients. The technology, which has been proven safe and efficacious in clinical trials carried out in Europe, allows companies to develop any kind of cells as a one-for-all living pharmaceutical. Bac-in-a-Box® is a similar protective device adapted for encapsulation of probiotic bacteria where it has human food and animal feed applications as well as rebalancing the microbiome due to its ability to extend storage under lyophilized conditions and to protect encapsulated bacteria against destruction by stomach acid. Austrianova now also offers GMP4Cells that includes competitively priced Master Cell Bank and Working Cell Bank production as well as “Fill and Finish” services for cell therapy products (such as stem cell therapies, biologics produced from cells e.g., vaccines, antibodies, enzymes, recombinant proteins, exosomes, etc.).
Contact
Brian Salmons information@austrianova.com

Categories
Diet / Health food / SupplementMedical / HospitalPharmaceuticalsVenture CapitalsLocal companies

Austrianova
URL
Industry
Health
Weekly Release Ranking
May 15, 2023 2023
Moolahgo enhances its FX product offerings with the ICE Consolidated Feed
Moolahgo Pte Ltd
VRITIMES Video
Free consultationManual EbookPR College